Table 2.
Selected patient and tumor characteristics
| |
Study population |
|---|---|
|
N = 940 | |
| N (%) | |
| Randomization arm |
|
| E-T-CMF |
454 (48.3) |
| E-CMF |
147 (15.6) |
| ET-CMF |
339 (36.1) |
| Age |
|
| <50 |
381 (40.5) |
| ≥50 |
559 (59.5) |
| Menopausal status |
|
| Premenopausal |
435 (46.3) |
| Postmenopausal |
505 (53.7) |
| Type of surgery |
|
| MRM |
644 (68.5) |
| Breast conserving |
296 (31.5) |
| Tumor size (cm) |
|
| ≤2 |
288 (30.6) |
| 2,1-5 |
530 (56.4) |
| >5 |
122 (13.0) |
| Histological type |
|
| Ductal |
727 (77.3) |
| Lobular |
97 (10.3) |
| Mixed |
72 (7.7) |
| Other |
44 (4.7) |
| N of positive nodes |
|
| 0-3 |
363 (38.6) |
| ≥4 |
577 (61.4) |
| Histological grade |
|
| I-II |
470 (50.0) |
| III-Undifferentiated |
470 (50.0) |
| Adjuvant HT |
|
| No |
178 (18.9) |
| Yes |
739 (78.6) |
| Missing data |
23 (2.4) |
| Adjuvant RT |
|
| No |
198 (21.1) |
| Yes |
711 (75.6) |
| Missing data | 31 (3.3) |
N, number; E, epirubicin; T, paxlitaxel; C, cyclophosphamide; M, methotrexate; F, 5-FU; MRM, modified radical mastectomy; HT, hormonal therapy; RT, radiotherapy.